دورية أكاديمية
Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients
| العنوان: | Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients |
|---|---|
| المؤلفون: | Çakal, Beytullah, Çakal, Sinem Deniz, Karaca, Oǧuz, Omaygenç, Mehmet Onur, Kızılırmak Yılmaz, Filiz, Güneş, Hacı Murat, Özcan, Özgür Ulaş, Yıldırım, Arzu, Boztosun, Bilal |
| بيانات النشر: | Termedia Publishing House Ltd. |
| سنة النشر: | 2020 |
| المجموعة: | İstanbul Medipol University Institutional Repository (DSpace@Medipol) |
| مصطلحات موضوعية: | Coronary Artery Disease, Percutaneous Coronary Intervention, Bioresorbable Scaffolds |
| الوصف: | Introduction: Elevated risk of adverse events in comparison to metallic stents resulted in withdrawal of everolimus-eluting bioresorbable scaffolds (eBVS), known as the most intensively studied BVS. There is a paucity of data comparing the two different BVS. Aim: To evaluate the long-term clinical outcomes of the novolimus-eluting bioresorbable vascular scaffold (nBVS) compared with eBVS. Material and methods: Consecutive patients treated with nBVS or eBVS in our center were screened. The primary outcome was the 3-year rate of major adverse cardiovascular events (MACE), defined as the composite of cardiac death, target vessel myocardial infarction (TV-MI), and target-lesion revascularization (TLR). Results: After matching, 98 patients treated with 135 eBVS were compared with 98 patients treated with 136 nBVS. Baseline characteristics, clinical presentation, and lesion characteristics were comparable in both groups. The 3-year MACE rate was higher in the eBVS group (17.3% vs. 6.1%; p log-rank = 0.02). The occurrence of TLR (16.3% vs. 5.1%; p log-rank = 0.02) and TV-MI (8.2% vs. 0 %; p log-rank = 0.004) was also higher in the eBVS group except for cardiac deaths (1% vs. 2%; p log-rank = 0.98, eBVS vs. nBVS, respectively). Of note, definite device thrombosis rate was markedly increased in the eBVS group (5.1% vs. 0%; p log-rank = 0.03). Conclusions: The present study revealed that the 3-year event risk was lower for nBVS compared to eBVS. More evidence is needed to evaluate long-term performance of novolimus-eluting biovascular platforms. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1734-9338 |
| العلاقة: | Postepy w Kardiologii Interwencyjnej; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; Çakal, B., Çakal, S. D., Karaca, O., Omaygenç, M. O., Kızılırmak Yılmaz, F., Güneş, H. M. . Boztosun, B. (2020). Long-term comparison of everolimus- vs. novolimus-eluting bioresorbable vascular scaffolds in real world patients. Postepy w Kardiologii Interwencyjnej, 16(4), 391-398. https://dx.doi.org/10.5114/aic.2020.101763Test; https://dx.doi.org/10.5114/aic.2020.101763Test; https://hdl.handle.net/20.500.12511/6554Test; 16; 391; 398; Q4; Q3 |
| DOI: | 10.5114/aic.2020.101763 |
| الإتاحة: | https://doi.org/20.500.12511/6554Test https://doi.org/10.5114/aic.2020.101763Test https://hdl.handle.net/20.500.12511/6554Test |
| حقوق: | info:eu-repo/semantics/openAccess ; Attribution-NonCommercial-ShareAlike 4.0 International ; https://creativecommons.org/licenses/by-nc-sa/4.0Test/ |
| رقم الانضمام: | edsbas.381A6E2E |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 17349338 |
|---|---|
| DOI: | 10.5114/aic.2020.101763 |